Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Termoablazione con ago a microonde per il trattamento del carcinoma prostatico localizzato

4 novembre 2026 aggiornato da: CHIU Ka Fung Peter, Chinese University of Hong Kong

Termoablazione con ago a microonde per il trattamento del cancro alla prostata localizzato sotto la guida del monitoraggio basato su organi di fusione a ultrasuoni e risonanza magnetica: una sperimentazione di fase 2.

Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the surrounding organs like rectum and bladder. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the target lesion without treating other benign areas, resulting in disease cure in majority of cases with less treatment morbidity. Microwave treatment to the prostate has been performed since more than 20 years ago for benign prostatic hyperplasia and is approved by FDA in United States. It exerts its effect through thermal destruction of prostate tissue. Targeted treatment of localized prostate cancer using microwave needle ablation guided by MRI and Ultrasound imaging has been performed recently and was shown to be safe and effective. Our study aims to assess the effectiveness of this focal therapy in treating localized prostate cancer.

Panoramica dello studio

Descrizione dettagliata

Prostate cancer screening with Prostate specific antigen (PSA) has resulted in an increase in the diagnosis of localized prostate cancer. The traditional approach for treating low-risk and intermediate-risk prostate cancer includes definitive treatment with either radical prostatectomy or radiotherapy, both of which are associated with considerable morbidity mainly in the area of genitourinary and bowel complications. Active surveillance is one of the options for early low grade prostate cancers, but about half of these men would convert to radical treatment in 10 years' time. In the case of localized intermediate risk prostate cancer, active surveillance is not a good option as it is associated with inferior oncological outcomes in subsequent radical treatment

Focal therapy for localized prostate cancer is the middle ground between active surveillance and radical treatment like prostatectomy or radiotherapy. Instead of monitoring a tumor to see when it is going to progress, focal therapy ablates the target lesion with the aim to reduce or avoid radical treatment. Although the efficacy of focal therapy appeared to be inferior to radical treatment with higher recurrence rates of 20-50%, repeated focal treatment is feasible and the complication profile of focal therapy was significantly better. A recent publication showed that in men with majority intermediate risk prostate cancer, 5 and 8-year freedom from radical treatment was 91% and 81%. This avoids the majority of patients with localized prostate cancer from receiving a radical treatment with potential complications. A recent consensus panel agreed that focal therapy should be defined as ablation of the dominant or index lesion only .

Numerous energy modalities have been utilized for focal therapy of prostate cancers, including High-intensity focused ultrasound (HIFU), Cryotherapy, Photodynamic therapy (PDT), Focal laser ablation (FLA), irreversible electroporation (IRE), and focal brachytherapy. All of them are still being considered experimental according to the latest international guideline due to inferior oncological outcomes (high recurrence and retreatment rates) and lack of long term data. The targeting mechanisms during focal therapies are largely cognitive after the operator read the MRI, resulting in limited precision and possible over or under-treatment. Under-treatment would result in residual disease and treatment failure, while over-treatment might result in complications similar to that in radical treatment. The limitation of MRI in revealing all significant tumors in the prostate and the inability to treat MRI-invisible tumors using existing focal therapy platforms also contributed to treatment failure. However, there is still a significant amount of focal therapies being performed worldwide due to its lower overall morbidity than radical treatment, feasibility of repeated focal treatment, and feasibility to proceed to radical treatment in treatment-failure cases.

Microwave treatment to prostate, Transurethral microwave therapy (TUMT), has been performed since more than 20 years ago for benign prostatic hyperplasia as an office procedure under local anaesthesia. It has not been used in prostate cancer treatment until recently a group in France conducted a single arm pilot study using organ-based tracking (OBT) MRI-Ultrasound fusion-guided microwave therapy using Koelis system for focal treatment of prostate cancer. (Clinical Trials number: NCT03023345) The treatment was done in 10 patients using microwave needles via transrectal route under general anaesthesia, with the primary outcome of complete necrosis of the index tumour on prostate MRI on day 7. The results were being reported in a conference paper, showing 80% (8/10) cases with complete necrosis of index tumor on day-7 MRI, and 20% (1/5) targeted biopsy of tumor showing residual low grade cancer at 6 months. No adverse event or complication occurred in all 10 cases.

MRI-Ultrasound fusion-guided prostate needle biopsy has been performed transperineally in Prince of Wales Hospital under routine basis. In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach under general anaesthesia. Most focal therapy modalities treat lesion that can be seen on MRI and confirmed on biopsy. In cases where significant cancer was located only on systematic biopsy but not on MRI, half or whole gland treatment is usually needed. In the microwave needle ablation guided by organ-based tracking (OBT) MRI-Ultrasound fusion using Koelis system, the positive systematic cores that is not visible on MRI can be accurately localized at the time of biopsy using Koelis system and treated subsequently.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Hong Kong, Hong Kong
        • Prince of Wales Hospital, Chinese University of Hong Kong

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 45 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Men aged between 45 - 75 years
  • Life expectancy > 10 years upon recruitment
  • Localized low or intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy
  • Organ-confined prostate cancer on MRI
  • PSA < 20 ng/mL
  • At least 1 MRI visible lesion present and size ≤15mm, and Targeted biopsy showing Gleason score 6 (with cancer core length ≥6mm) or Gleason score 7 (3+4 or 4+3), With or without positive Systematic biopsy (out of 24 systematic cores) away from MRI visible target showing Gleason 6 cancer

Exclusion Criteria:

  • Patients unfit for MRI exam or MR gadolinium contrast
  • Patients with previous treatment of prostate cancer
  • Patients with maximal length of target lesion >15mm
  • Patients with MRI-visible or invisible lesion within 10mm from rectum or 10mm from sphincter on MRI
  • Patients with >3 areas (MRI-visible or invisible) of prostate cancer
  • Patients with Gleason score 4+4 or any Gleason pattern 5 cancer
  • Patients with bladder pathology including bladder stone and bladder cancer
  • Patients with urethral stricture
  • Patients with neurogenic bladder and/or sphincter abnormalities

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Microwave needle thermoablation of prostate cancer

The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.

In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The oncological control of prostate cancer
Lasso di tempo: At 6 months after treatment

Any cancer detected on biopsy of each ablated area

At 6 months after treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Per-patient analysis of any cancer detected on biopsy of any ablated areas
Lasso di tempo: At 6 months after treatment

Per-patient analysis of any cancer detected on biopsy of any ablated areas

At 6 months after treatment
Cancer detection on biopsy of each ablated MRI visible lesion
Lasso di tempo: At 6 months after treatment

Cancer detection on biopsy of each ablated MRI visible lesion

At 6 months after treatment
Cancer detection on biopsy of each ablated MRI invisible lesion
Lasso di tempo: At 6 months after treatment

Cancer detection on biopsy of each ablated MRI invisible lesion

At 6 months after treatment
Gleason 4 or 5 cancer detected on biopsy of ablated area
Lasso di tempo: At 6 months after treatment

Gleason 4 or 5 cancer detected on biopsy of ablated area

At 6 months after treatment
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy
Lasso di tempo: At 6 months after treatment

Out-of-field recurrence: Any cancer outside treated area on systematic biopsy

At 6 months after treatment
Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Lasso di tempo: 1 year

Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0

1 year
Dimension of necrosis area on MRI
Lasso di tempo: At 1 week

Dimension of necrosis area on MRI

At 1 week
PSA change
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

PSA change after treatment

At baseline, 4 weeks, 3 months, 6 months and 12 months
International Prostate Symptom Score (IPSS) score
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

Urinary symptoms measured by IPSS score, score ranging from 0-35 (the higher the worse)

At baseline, 4 weeks, 3 months, 6 months and 12 months
Sexual side effects, up to 1 year, measured by International Index of Erectile Function 5-item version (IIEF-5) score
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

Sexual side effects, up to 1 year, measured by IIEF-5 score (ranging from 1-25), the lower the worse

At baseline, 4 weeks, 3 months, 6 months and 12 months
Expanded Prostate cancer Index Composite (EPIC-26) questionnaire
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

Quality of life in patients with prostate cancer measured by EPIC-26, range 0-100, the higher score the better the quality of life

At baseline, 4 weeks, 3 months, 6 months and 12 months
Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

Rectal side effects measured by CTCAE rectal toxicity, Grade 1-5 for any rectal toxicity, the higher the score the more severe the toxicity

At baseline, 4 weeks, 3 months, 6 months and 12 months
EQ-5D (EuroQol 5 dimensions) questionnaire
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

Quality of life measured by ED-5Q questionnaire, with 5 components [Mobility, Self Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression)], and a Visual analogue scale (EQ-VAS) score, the higher the score the better in quality of life

At baseline, 4 weeks, 3 months, 6 months and 12 months
QLQ-C30 (Quality of life Core 30) questionnaire
Lasso di tempo: At baseline, 4 weeks, 3 months, 6 months and 12 months

Quality of life measured by QLQ-C30, score 0-100, the higher the score the better in quality of life

At baseline, 4 weeks, 3 months, 6 months and 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Peter KF Chiu, MBChB,FRCSEd, Chinese University of Hong Kong

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 ottobre 2019

Completamento primario (Effettivo)

16 febbraio 2023

Completamento dello studio (Effettivo)

11 aprile 2023

Date di iscrizione allo studio

Primo inviato

1 ottobre 2019

Primo inviato che soddisfa i criteri di controllo qualità

1 ottobre 2019

Primo Inserito (Effettivo)

3 ottobre 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 maggio 2025

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi